Navigation Links
Circassia's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results
Date:3/8/2012

OXFORD, England, March 8, 2012 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.  In the study, patients with more severe symptoms achieved a significantly greater improvement following treatment with the ToleroMune® T-cell vaccine than those on placebo (p≤0.05).  The results were presented at the 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology*.  

"The results of this key phase II study are highly encouraging, because they show our ToleroMune ragweed allergy vaccine can reduce patients' symptoms after just a short course of treatment and, most importantly, offers the greatest improvement to those who can benefit most," said Steve Harris, Circassia's CEO. "We have now achieved successful phase II results with four of our allergy T-cell vaccines, which validate our scientific approach and give us the confidence to progress our lead programmes into the final phase of development."

Circassia's latest phase II study was designed to assess the T-cell vaccine's efficacy and tolerability and to identify the optimal treatment regime.  The trial was conducted in Canada in 275 ragweed allergy patients.  During the randomised, double-blind, placebo-controlled trial, volunteers received one of four regimens of ToleroMune treatment over a three-month period.  Patients were exposed to ragweed allergens in a validated exposure chamber, and investigators compared their nasal and ocular symptoms against the pre-treatment baseline.  The results show that the T-cell vaccine's optimal regimen substantially reduced patients' symptoms, achieving a 97% greater reduction than placebo (p≤0.05) in subjects who had a moderate level of symptoms at baseline.  The treatment was safe and well tolerated in all groups.  

About Circassia's allergy T-cell vaccines

Circassia is developing a range of allergy treatments based on its proprietary ToleroMune® technology, which utilises small sections of allergens (epitopes) to generate regulatory T cells that suppress allergic immune responses, and thereby desensitise patients.  The company has successfully completed a number of phase II studies with its cat, house dust mite, ragweed and grass allergy therapies.  Clinical results show that short treatment regimes with Circassia's T-cell vaccines can greatly reduce patients' allergic responses, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated.  As a result, the treatments offer major potential clinical benefits compared with existing therapies, and have significant market opportunities.  More than 150 million people suffer from allergic rhinitis in the US and Europe, and over 25% of the population of the United States and a growing number of Europeans are sensitive to ragweed pollen.  As a result, the current allergy treatment market is valued at approximately $12 billion per year.  

About Circassia

Circassia was founded in 2006 by a team of highly experienced biotechnology scientists and entrepreneurs, and is chaired by the former Chairman of GlaxoSmithKline, Sir Richard Sykes.  The company is based in the UK on the Oxford Science Park, and in Hamilton, Canada, where its joint venture Adiga Life Sciences is located.  Its ToleroMune technology was developed originally by scientists at Imperial College, London.  Having successfully completed four fundraising rounds, Circassia has raised approximately £93 million ($159 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.

* Hafner R et al.  Validation of peptide immunotherapy as a new approach in the treatment of allergic rhinoconjunctivitis: The clinical benefits of treatment with Amb a 1 derived T cell epitopes.

Contacts

Steve Harris
CEO
Circassia
Tel: +44(0)1865-784574
http://www.circassia.co.uk 

 

Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241



'/>"/>
SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
2. Cold, Flu and Allergy Sufferers Can Select the Best Over-the-Counter Medications with Help from Pharmacists
3. AllergEase LLC Launches All-Natural Lozenges for Seasonal Allergy Sufferers
4. SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases
5. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
6. Perrigo Company to Attend the 2011 Annual Meeting of the American College of Allergy, Asthma & Immunology
7. Jubilant HollisterStier Allergy Launches Allergy Industry Insights Educational Webinar Series
8. Allegra® and Survivor Winner Danni Boatwright Want to Hear About Your "Allergy Adventures"
9. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
10. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
11. Cobalis Corp. Launches National Television Commercials for PreHistin® Allergy Defense Formula
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... YORK , April 19, 2017 Global ... drainage devices are tubes used to remove excess liquid ... blood, serum, pus, urine, bile or lymph. Surgical drains ... of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, ... is prophylactic post-surgery to prevent accumulation of fluid e.g. ...
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... 2017 Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Uro/Gyn and Gynecology markets with innovative and proprietary products, ... March 31, 2017 after the market close on Tuesday, ... host a conference call and webcast to discuss its ... 2017 at 4:30 p.m. Eastern Time (3:30 p.m. Central ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers of ... pain with a reputable physician in their area, announces the launch of a new ... for patients who are looking for reputable physicians to help them with back or ...
(Date:4/25/2017)... NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed ... treatment of acute or chronic problems, I focus on preventative care with all my patients ... you have any questions, always feel free to contact my office and my trained staff ...
(Date:4/25/2017)... ... 25, 2017 , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley ... in Writing, set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, ... Arizona College of Medicine. He also serves as Medical Director for the Bureau of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
Breaking Medicine News(10 mins):